Manages vasospastic angina confirmed. ANDA 203126, held by Twi Pharms. Nifedipine.
As of Nov 16, 2026, ANDA 203126 (Nifedipine), held by Twi Pharms, was first approved by FDA on Apr 3, 2014, with 2 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE I. Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 3, 2014 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
| Nov 24, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 24, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 3, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters